News
The day at a glance · 2 min read
Mood · Cautious
+10
Sentiment, −100 to +100
BMY NSCLC PFS improvement
Doubled vs chemo
LLY pre-earnings move
2.5%-2.5%
MRNA 12-month gain
~7x
Key driverMajor Big Pharma earnings reports scheduled this week amid pipeline developments and patent cliff concerns
Daily briefHealthcare· Money365.Market AI ·

Big Pharma Earnings Loom; BMY Lung Cancer Data Positive

Bristol Myers reports Phase 3 progression-free survival doubling; Eli Lilly, Merck, AbbVie earnings this week

Big Pharma & Biotech

Neutral
01BMY▼ -2.41%
Bristol-Myers Squibb ($BMY) announced that izalontamab brengitecan doubled median progression-free survival compared to chemotherapy in patients with previously-treated EGFR-mutated non-small cell lung cancer in the Phase 3 PANKU-Lung01 study. The company is trading below 10 times forward earnings as it faces a patent cliff, a common challenge in the pharmaceutical sector.
02LLY▼ -2.54%
Eli Lilly ($LLY) stock fell 2.5% ahead of its Q3 earnings report scheduled for Thursday. Analysts suggest revenue could face pressure even as patient numbers grow, with the stock currently at approximately $1,273 against a street target of around $1,330 and a mid-range target of approximately $2,220.
03JNJ
Johnson & Johnson ($JNJ) won UK approval for its psoriasis pill, with the stock trading at approximately $263 against a mid-range target of around $342 and a street target of approximately $279. The potential total return is estimated at approximately 30%.
04MRNA
Moderna ($MRNA) has delivered significant gains over the past 12 months, with the stock rising by roughly 7 times, though headlines around melanoma vaccine trial data leaks have raised questions about current valuation levels. Attention has shifted to whether the current share price is supported by anticipated sales.
05BNTX
BioNTech ($BNTX) and Gilead Sciences ($GILD) agreed to a clinical trial collaboration to study pumitamig with sacituzumab govitecan in first-line metastatic triple-negative breast cancer. The partners plan to adapt an existing global Phase 3 trial of pumitamig to reflect current clinical standards, marking the first worldwide Phase 3 study to test pumitamig in combination with an antibody-drug conjugate.

Earnings & Pipeline Watch

Neutral

MRK Q2 revenue

$16.61B+5.07%

MRK Q2 consensus

$16.37B
01MRK
Merck ($MRK) reports third-quarter results on Thursday, October 29, with analysts focused on whether newer product launches are growing fast enough to cushion Keytruda's 2028 patent loss. Last quarter, revenue rose 5.07% to $16.61 billion, beating the $16.37 billion consensus.
02ABBV
AbbVie ($ABBV) is scheduled to report earnings on Friday, with the stock remaining attractive to investors despite its high price relative to earnings. The company maintains its status as a dividend king with continued dividend growth.

Looking Ahead

Neutral
01LLY▼ -2.54%
This week represents the busiest earnings period of the quarter for healthcare, with Eli Lilly ($LLY) and Merck ($MRK) reporting on Thursday, followed by AbbVie ($ABBV) on Friday. Two FDA deadlines are also expected this week, adding to the sector's catalysts.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy